2-(4-(2-bromoethoxy)phenyl)ethanol | 1254103-17-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2-(4-(2-bromoethoxy)phenyl)ethanol
• 英文别名: 2-[4-(2-Bromoethoxy)phenyl]ethanol
• CAS: 1254103-17-7
• 化学式: C₁₀H₁₃BrO₂
• 分子量: 245.116
• InChiKey: QZPYLKVLYMVWPL-UHFFFAOYSA-N

物化性质

• 沸点：
  340.8±27.0 °C(Predicted)
• 密度：
  1.413±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-(2-bromoethoxy)phenyl)ethanol 在 N-甲基吗啉 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 16.0h， 生成 (R)-(-)-3-[(R)-2-benzyloxyformoxy-2-cyclopentyl-2-phenylethoxy]-1-[2-(4-methylsulfonyloxyethylphenoxy)ethyl]-1-azoniabicyclo[2.2.2]octane bromide
  参考文献：
  名称：

  CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE

  摘要：

  公开号：

  EP3556435B1
• 作为产物：
  描述：

  4-羟基苯乙酸甲酯 在 sodium tetrahydroborate 、 碳酸氢钠 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 9.0h， 生成 2-(4-(2-bromoethoxy)phenyl)ethanol
  参考文献：
  名称：

  CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE

  摘要：

  公开号：

  EP3556435B1

文献信息

• Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity
  作者：Xian-xuan Liu、Yan-ting Yang、Xiao Wang、Kai-yi Wang、Jia-qi Liu、Lei Lei、Xiao-min Luo、Rong Zhai、Feng-hua Fu、Hong-bo Wang、Yi Bi

  DOI：10.1016/j.ejmech.2017.09.016

  日期：2017.12

  potent cytotoxic agent than the parent compound α-hederagenin (H), 24 α-hederagenin derivatives (5–8, 11–24, 27–28, 31–32, and 35–36) were synthesized in a concise and efficient strategy and screened for in vitro cytotoxicity against the human cancer cell lines MKN45 and KB. Among these compounds, the polyamine derivative 15 exhibited more potency than the parent compound with IC50 values in the range

  在试图在比母体化合物α-常春配基的更有效的细胞毒性剂（到达ħ），24 α -hederagenin衍生物（5 - 8，11 - 24，27 - 28，31 - 32，和35 - 36）为以简洁有效的策略合成了该化合物，并筛选了针对人类癌细胞系MKN45和KB的体外细胞毒性。在这些化合物中，多胺衍生物15的效能比具有IC 50的母体化合物更高值在4.22 μM–8.05μM的范围内。化合物15增加了Bax / bcl-2的比率，从而破坏了线粒体的电位并诱导了细胞凋亡。因此，本研究强调了α-角豆生成素的多胺衍生物在新型抗癌剂的发现和开发中的重要性。
• Discovery and synthesis of 3- and 21-substituted fusidic acid derivatives as reversal agents of P-glycoprotein-mediated multidrug resistance
  作者：Mengqi Guo、Qianwen Ren、Binghua Wang、Wentao Ji、Jingxuan Ni、Yaqi Feng、Yi Bi、Jingwei Tian、Hongbo Wang

  DOI：10.1016/j.ejmech.2019.111668

  日期：2019.11

  In this study, we synthesized 23 fusidic acid (FA) derivatives and screened them for tumor drug resistance reversal activity and cytotoxicity toward the KBV (multidrug-resistant oral epidermoid carcinoma) cell line based on MTT assay. Tumor resistance reversal activity of fusidic acid (FA) derivatives was discovered for the first time. Our results showed that compound 1 enhanced the cytotoxicity of

  在这项研究中，我们合成了23种夫西地酸（FA）衍生物，并根据MTT分析筛选了它们对KBV（多药耐药口腔表皮样癌）细胞系的肿瘤耐药逆转活性和细胞毒性。首次发现了夫西地酸（FA）衍生物的抗肿瘤逆转活性。我们的结果表明，化合物1以5μM的浓度增强了紫杉醇对耐药KBV细胞的细胞毒性。化合物1使KBV细胞对紫杉醇敏感，使其停滞在G2 / M期并诱导细胞凋亡。进一步的研究表明，化合物1通过增加P-gp的ATPase活性来抑制P-糖蛋白（P-gp）的药物外排活性，而不影响其表达。还初步研究了FA衍生物的构效关系（SAR）。我们的发现表明，化合物1是用于设计未来具有改善的肿瘤耐药性逆转活性的FA衍生物的有前途的先导化合物。
• New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
  申请人：Almirall, S.A.

  公开号：EP2386555A1

  公开（公告）日：2011-11-16

  The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

  本发明涉及具有β2肾上腺素受体激动剂和M3肌样受体拮抗剂双重活性的新化合物，包含它们的药物组合物，它们的制备过程以及它们在呼吸疗法中的应用。
• QUATERNARY AMMONIUM SALT COMPOUNDS
  申请人：Mitsuyama Etsuko

  公开号：US20120046467A1

  公开（公告）日：2012-02-23

  [Problem] The object of the present invention is to provide a novel compound having 132 adrenergic receptor agonist activity and muscarinic receptor antagonist activity. [Means for Solving the Problem] The present invention is a quaternary ammonium salt compounds represented by formula (I), or a pharmaceutically acceptable salt thereof, with superior β32 adrenergic receptor agonist activity and muscarinic receptor antagonist activity.

  本发明的目的是提供一种具有132肾上腺素受体激动剂活性和肌制剂受体拮抗活性的新型化合物。本发明是一种由化学式(I)表示的季铵盐化合物，或其在药学上可接受的盐，具有优越的β32肾上腺素受体激动剂活性和肌制受体拮抗活性。
• Design, Synthesis, In Silico and In Vitro Studies for New Nitric Oxide-Releasing Indomethacin Derivatives with 1,3,4-Oxadiazole-2-thiol Scaffold
  作者：Alexandru Sava、Frederic Buron、Sylvain Routier、Alina Panainte、Nela Bibire、Sandra Mădălina Constantin、Florentina Geanina Lupașcu、Alin Viorel Focșa、Lenuţa Profire

  DOI：10.3390/ijms22137079

  日期：——

  Starting from indomethacin (IND), one of the most prescribed non-steroidal anti-inflammatory drugs (NSAIDs), new nitric oxide-releasing indomethacin derivatives with 1,3,4-oxadiazole-2-thiol scaffold (NO-IND-OXDs, 8a–p) have been developed as a safer and more efficient multitarget therapeutic strategy. The successful synthesis of designed compounds (intermediaries and finals) was proved by complete spectroscopic analyses. In order to study the in silico interaction of NO-IND-OXDs with cyclooxygenase isoenzymes, a molecular docking study, using AutoDock 4.2.6 software, was performed. Moreover, their biological characterization, based on in vitro assays, in terms of thermal denaturation of serum proteins, antioxidant effects and the NO releasing capacity, was also performed. Based on docking results, 8k, 8l and 8m proved to be the best interaction for the COX-2 (cyclooxygense-2) target site, with an improved docking score compared with celecoxib. Referring to the thermal denaturation of serum proteins and antioxidant effects, all the tested compounds were more active than IND and aspirin, used as references. In addition, the compounds 8c, 8h, 8i, 8m, 8n and 8o showed increased capacity to release NO, which means they are safer in terms of gastrointestinal side effects.

  从消炎痛（IND）开始，这是最常被开处方的非甾体类抗炎药（NSAIDs）之一，新的一氧化氮释放消炎痛衍生物具有1,3,4-噁二唑-2-硫代骨架（NO-IND-OXDs，8a–p），作为更安全和更有效的多靶点治疗策略已经被开发出来。设计的化合物（中间体和最终体）的成功合成通过完整的光谱分析得以证明。为了研究NO-IND-OXDs与环氧合酶同功酶的体外相互作用，进行了分子对接研究，使用AutoDock 4.2.6软件进行。此外，基于体外实验的生物学特性评价，包括血清蛋白的热变性、抗氧化效果和一氧化氮释放能力也进行了。根据对接结果，8k、8l和8m证明在COX-2（环氧合酶-2）靶点上具有最佳的相互作用，与司来柔胺相比具有改善的对接分数。关于血清蛋白的热变性和抗氧化效果，所有测试的化合物都比IND和阿司匹林更活跃，作为参考。此外，化合物8c、8h、8i、8m、8n和8o显示出增加释放NO的能力，这意味着它们在胃肠道副作用方面更安全。